Stevanato Group S.p.A. (STVN)is a renowned global provider of drug containment, drug delivery, and diagnostic solutions aimed at improving the health and well-being of patients. The company has its roots in Italy and was founded by Sergio Stevanato in 1949 where it started as a small artisan workshop producing glassware and components for the lighting industry. Since then, the company has significantly transformed and evolved into a leading provider that serves the pharmaceutical and healthcare industry on a global scale.
The company currently operates through two interconnected business branches - Pharmaceutical Systems and Engineering Systems. The former deals with the production and distribution of glass containers, such as vials and syringes, while the latter is responsible for providing machines and technology solutions for glass forming and inspection.
Stevanato Group S.p.A. has benefitted enormously from its long-lasting partnerships with pharmaceutical and biotechnology companies. It is the supplier behind innovative drug delivery systems, rigid sterile containers, and integrated analytical lab services. Through its offerings, Stevanato Group aims to ensure the safest and most efficient delivery of drugs to patients and has hence contributed broadly to global health outcomes.
The company's commitment to quality and safety is underlined by its numerous certifications, including ISO standards, which demonstrate adherences to regulatory requirements and international quality systems. This emphasis on quality has seen the company establish manufacturing facilities and commercial offices in 14 countries across Europe, the Americas, and Asia, reflecting its truly global presence.
Stevanato Group is also actively involved in research and development initiatives, which include collaborations with research institutions and pharmaceutical companies to advance the frontiers of healthcare. The company has a dedicated team of professionals working on various patents and projects developing cutting-edge technologies, further cementing Stevanato Group’s reputation as an innovative leader in the industry.
With its rich history, vast global presence, and commitment to delivering high-quality healthcare solutions, Stevanato Group S.p.A. continually demonstrates its ambition to shape the future of the pharmaceutical and healthcare industries.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Van Berkom & Associates Inc. reduced its stake in Stevanato Group S.p.A. by 3.7% in the third quarter, selling 110,897 shares but still retaining over 2.8 million shares valued at about $60 million. The company reported quarterly EPS of €0.16, missing analyst expectations, while insider Mauro Stocchi also sold 13,649 shares, decreasing his direct holdings by 3.3%. Despite mixed analyst views, Stevanato Group maintains a "Moderate Buy" consensus rating on MarketBeat.
William Blair has downgraded Stevanato Group S.p.A. (NYSE: STVN) from Outperform to Market Perform, removing a buy-side rating. Historically, STVN's stock has closed lower in 17 out of 23 sessions following previous headlines, with a median move of 1.7% in either direction. The stock saw a significant drop of 28.6% after its Q3 2026 earnings report on November 3, 2026.
SueWallSt has announced a pending investigation into Stevanato Group S.p.A. (NYSE: STVN) following a sharp decline in its shares on November 3, 2026. The fall was triggered by the company's third-quarter report, which included a lower outlook for GLP-1 related volume in 2027, contradicting previous statements about "durable tailwinds" from its GLP portfolio. The investigation will examine whether Stevanato Group's disclosures to investors met U.S. securities law requirements.
Stevanato Group SpA reported strong third-quarter earnings of $48.1 million, or 17 cents per share, surpassing Wall Street expectations. Adjusted earnings were 18 cents per share, exceeding the average analyst estimate of 17 cents. The company, a maker of glass vials for vaccines, posted revenue of $375.3 million and provided full-year earnings guidance between 69 and 71 cents per share with revenue in the range of $1.45 billion to $1.47 billion.
Schwartz Investment Counsel Inc. significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) during the third quarter of 2026, adding 86,385 shares to own a total of 661,136 shares valued at $13.9 million. This move aligns with several other institutional investors who have expanded or initiated positions in the company. Despite reporting slightly below-consensus quarterly EPS, analysts maintain a "Moderate Buy" rating for Stevanato Group, with projected full-year EPS of €0.69.